Androgen Pathway Manipulation and Survival in Patients with Lung Cancer

Sex as an Independent Prognostic Factor in a Population-Based, Non-Small Cell Lung Cancer Cohort

(2016) Marshall W Pitz et al.   Canadian Respiratory Journal

Challenges of Guarantee-Time Bias

(2013) Anita Giobbie-Hurder et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Survival of Participants in the Prostate Cancer Prevention Trial

(2013) Ian M. Thompson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Research Resource: Diagnostic and Therapeutic Potential of Nuclear Receptor Expression in Lung Cancer

(2012) Yangsik Jeong et al.   MOLECULAR ENDOCRINOLOGY

The prognostic impact of tumor cell expression of estrogen receptor-α, progesterone receptor, and androgen receptor in patients irradiated for nonsmall cell lung cancer

(2011) Dirk Rades et al.   CANCER

5α-reductase type 3 expression in human benign and malignant tissues: A comparative analysis during prostate cancer progression

(2010) Alejandro Godoy et al.   PROSTATE

Androgen receptor and androgen-dependent gene expression in lung

(2009) Laura Mikkonen et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lung cancer in women: the differences in epidemiology, biology and treatment outcomes

(2009) Maria Patricia Rivera   Expert Review of Respiratory Medicine

A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells

(2008) Anna Grazia Recchia et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY